| Authors: |
Kane JM; The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA; Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, NY, USA. Electronic address: jkane2@northwell.edu., Harary E; Teva Pharmaceutical Industries, Global Specialty Research & Development, Netanya, Israel., Eshet R; Teva Pharmaceutical Industries, Global Specialty Research & Development, Netanya, Israel., Tohami O; Teva Pharmaceutical Industries, Global Specialty Research & Development, Netanya, Israel., Weiser M; Sheba Medical Center, Department of Psychiatry, Tel Hashomer, Israel; Sackler School of Medicine at Tel Aviv University, Department of Psychiatry, Tel Aviv, Israel., Leucht S; Technical University of Munich, School of Medicine, Department of Psychiatry and Psychotherapy, Munich, Germany., Merenlender-Wagner A; Teva Pharmaceutical Industries, Global Specialty Research & Development, Netanya, Israel., Sharon N; Teva Pharmaceutical Industries, Global Specialty Research & Development, Netanya, Israel., Davis GL 3rd; Teva Branded Pharmaceutical Products R&D, Global Clinical Operations, West Chester, PA, USA., Suett M; Teva UK, Global Medical Affairs, Harlow, UK., Franzenburg KR; Teva Branded Pharmaceutical Products R&D, Global Medical Affairs, West Chester, PA, USA., Correll CU; The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA; Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, NY, USA; Charité-Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany. |
